Josephine M. Anderson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Josephine M. Anderson has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Cameron R. Currie
McMaster University
1 shared publication - David J. Aceti
Small Molecule Screening Facility, UW Carbone Cancer Center, Madison, WI 53792, USA
1 shared publication - David R. Andes
Department of Medicine, University of Wisconsin-Madison, Madison, USA
1 shared publication - Doug R. Braun
Pharmaceutical Sciences Division, University of Wisconsin–Madison, Madison, WI 53705, USA
1 shared publication - Nathaniel J. Brittin
Pharmaceutical Sciences Division, University of Wisconsin—Madison, Madison, WI 53705, USA
1 shared publication - Scott R. Rajski
Pharmaceutical Sciences Division, University of Wisconsin–Madison, Madison, WI 53705, USA
1 shared publication
Latest Publications
- Open Access
Dereplication of Natural Product Antifungals via Liquid Chromatography–Tandem Mass Spectrometry and Chemical Genomics
Recently expanded reports of multidrug-resistant fungal infections underscore the need to develop new and more efficient methods for antifungal drug discovery. A ubiquitous problem in natural product drug discovery campaigns is the rediscovery of known compounds or their relatives; accordingly, we have integrated Liquid Chromatography–Tandem Mass Spectrometry (LC-MS/MS) for structural dereplication and Yeast Chemical Genomics for bioprocess evaluation into a screening platform to identify such compounds early in the screening process. We identified 450 fractions inhibiting Candida albicans and the resistant strains of C. auris and C. glabrata among more than 40,000 natural product fractions. LC-MS/MS and chemical genomics were then used to identify those with known chemistry and mechanisms of action. The parallel deployment of these orthogonal methods improved the detection of unwanted compound classes over the methods applied individually.
Open AccessDereplication of Natural Product Antifungals via Liquid Chromatography–Tandem Mass Spectrometry and Chemical Genomics
Recently expanded reports of multidrug-resistant fungal infections underscore the need to develop new and more efficient methods for antifungal drug discovery. A ubiquitous problem in natural product drug discovery campaigns is the rediscovery of known compounds or their relatives; accordingly, we have integrated Liquid Chromatography–Tandem Mass Spectrometry (LC-MS/MS) for structural dereplication and Yeast Chemical Genomics for bioprocess evaluation into a screening platform to identify such compounds early in the screening process. We identified 450 fractions inhibiting Candida albicans and the resistant strains of C. auris and C. glabrata among more than 40,000 natural product fractions. LC-MS/MS and chemical genomics were then used to identify those with known chemistry and mechanisms of action. The parallel deployment of these orthogonal methods improved the detection of unwanted compound classes over the methods applied individually.